Table 5.
Common adverse events in intermittent androgen deprivation therapy (IADT) and continuous androgen deprivation therapy (CADT) groups (% patients, ≥5% in any group).
| Adverse events | SEUG 9401 [20] |
TULP [24] |
Finn Prostate [23]a |
TAP 22 [22] |
SEUG 9901 [21] |
|||||
|---|---|---|---|---|---|---|---|---|---|---|
| IADT (n = 299) | CADT (n = 293) | IADT (n = 97) | CADT (n = 96) | IADT (n = 274) | CADT (n = 280) | IADT (n = 96) |
CADT (n = 94) |
IADT (n = 436) |
CADT (n = 421) |
|
| Anemia | 4 | 5 | ||||||||
| Atrial fibrillation | 5.5 | 5.7 | ||||||||
| Bone pain | 13.5 | – | ||||||||
| Brain infarction | 8.8 | 11.1 | ||||||||
| Bronchitis | ||||||||||
| Cardiac failure | 7.7 | 6.4 | ||||||||
| Constipation | 7 | 17 | ||||||||
| Coronary artery disease | 7.7 | 10.7 | ||||||||
| Diarrhea | ||||||||||
| Depression | 6 | 11 | ||||||||
| Dyspnea | 6 | 12 | ||||||||
| Erectile dysfunction | 9 | 10 | ||||||||
| Gynecomastia | 12.4 | 19.5 | 4 | 7 | 13.8 | 37.3 | ||||
| Headache | 7.4 | 12.3 | 32.3 | 46.8 | 8.0 | 15.9 | ||||
| Hot flushes | 19.7 | 30 | 50 | 59 | 60.4 | 63.8 | 8.3 | 24.9 | ||
| Hypertension | ||||||||||
| Increased liver enzyme | 8 | 5 | ||||||||
| Injection site reaction | ||||||||||
| Joint pain | – | 13.8 | ||||||||
| Lumbar pain | 12.5 | 13.8 | ||||||||
| Myocardial infarction | 6.9 | 7.9 | ||||||||
| Nasopharyngitis | ||||||||||
| Nausea | 11 | 20 | ||||||||
| Other | 10.4 | 8.9 | 11.0 | 12.8 | ||||||
| Other brain circulatory disorders | 5.5 | 2.1 | ||||||||
| Other singular vascular disorders | 5.1 | 3.9 | ||||||||
| Pruritus | ||||||||||
| Skin complaints | 2.7 | 6.8 | 0.7 | 1.7 | ||||||
| Urinary incontinence | ||||||||||
| Visual disturbances | 33 | 33 | ||||||||
| Weight gain | ||||||||||
a
Cardiovascular adverse events only.